Biodyne Co

Biodyne Co FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Biodyne Co (314930.KQ) as of Nov 3, 2026 is -564.43 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 3,140.73 % — a change of -117.97% (lower).

FCF Conversion

-564.43 %

YoY

-117.97%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Biodyne Co is 2025 -564.43 % . FCF Conversion Rate (FCF/EBITDA) of Biodyne Co was 2024 3,140.73 % . It decreases by -117.97% lower compared to the previous year.

The Biodyne Co FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
18.28 KRW
Jan 1, 2019
338.16 KRW
Jan 1, 2020
17.06 KRW
Jan 1, 2021
12.35 KRW
Jan 1, 2022
20.51 KRW
Jan 1, 2023
26.69 KRW
Jan 1, 2024
3,140.73 KRW
Jan 1, 2025
-564.43 KRW
The Biodyne Co FCF Conversion history
YEARFCF ConversionYoY
-564.43 %-117.97%
3,140.73 %+11,667.42%
26.69 %+30.14%
20.51 %+66.07%
12.35 %-27.60%
17.06 %-94.96%
338.16 %+1,750.09%
18.28 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biodyne Co Stock analysis

What does Biodyne Co do? Biodyne Co., Ltd. develops and sells cancer diagnosis solutions, including LBC diagnostic equipment and diagnostic reagent kits. The company's equipment lineup features PATHPLORER AUTO, PATHPLORER 4.7, PATHPLORER 4.63, and PATHPLORER ECO, targeting healthcare providers in domestic and international markets. Products are sold in Japan, Russia, Portugal, and Thailand, with domestic sales complementing overseas distribution. Revenue is generated through direct sales of diagnostic equipment and reagent kits to medical facilities and laboratories. Biodyne's primary customers are healthcare institutions requiring cancer screening and diagnostic tools, including hospitals and clinical laboratories. The firm's domestic market presence supports its international expansion into regions like Japan and Russia, where demand for advanced diagnostic solutions is growing. Sales of PATHPLORER series equipment and reagent kits form the core revenue streams, with no additional services or licensing models mentioned. The company focuses on a niche segment of cancer diagnostics, leveraging its equipment and reagent kits to serve both local and global healthcare systems. By offering standardized diagnostic solutions, Biodyne caters to the needs of medical professionals seeking reliable and efficient cancer detection methods. International markets such as Portugal and Thailand represent key growth areas alongside established domestic operations. Biodyne Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biodyne Co stock

FCF Conversion Rate (FCF/EBITDA) of Biodyne Co is -564.43 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Biodyne Co changed from 3,140.73 % to -564.43 %, representing a -117.97% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Biodyne Co since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Biodyne Co with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Biodyne Co

All Key Metrics — Biodyne Co